‘Sham’ or public interest? ICER suggests 70%-plus discounts on Vertex’s cystic fibrosis drugs
admin 4th May 2018 Uncategorised 0Vertex has often talked about its admiration of Gilead, setting the big biotech’s ability to roll out multiple antivirals as a model for its cystic fibrosis endeavor. Now, though, it faces the same pricing issue the cost-effectiveness watchdog ICER once pinned on Gilead’s hepatitis C franchise. But the company refuses to play sitting duck.
More: ‘Sham’ or public interest? ICER suggests 70%-plus discounts on Vertex’s cystic fibrosis drugs
Source: fierce